Peginterferon Beta-1a (Plegridy)
Peginterferon beta-1a (Plegridy) is a medication administered by subcutaneous (SC) injection, every two weeks, for the treatment of relapsing forms of MS. Interferon beta-1a pegylanted is theorized to down-regulate proinflammatory cytokines, decrease major histocompatibility antigens, and reduce T-lymphocyte passage across the blood-brain-barrier. Pegylation results in longer effective half-life and, thus, extended dosing intervals. It also reduces formation of neutralizing interferon antibodies (NAbs).
Additional Information
Disclaimer: Links are provided as a convenience and for informational purposes only. They do not constitute an endorsement or an approval by MSCoE of any of the products, services, or opinions of the organization. MSCoE bears no responsibility for the accuracy, legality, or content of the external site or for that of subsequent links. Contact the external site for answers to questions regarding its content.
